NCT05313802

A Study of LY3502970 in Healthy Overweight and Obese Participants

A Multiple Dose Study in Healthy Overweight and Obese Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

Conditions

• Healthy
• Obese

Interventions

Type	Name	Description
DRUG	LY3502970	Administered orally.

Timeline

• Start date: 2022-05-26
• Primary completion: 2022-09-09
• Completion: 2022-09-09
• First posted: 2022-04-06
• Last updated: 2022-10-18

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study